FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs

Targeted Oncology

AIMode News Desk · curated summary

August 11, 20261 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs Targeted Oncology

About this story

This story was aggregated from Targeted Oncology. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

More in Health

Health

Seattle Children’s gets $700k in grants for pediatric cancer research

Related coverage: Seattle Children’s gets $700k in grants for pediatric cancer research kiro7.com

kiro7.com · 3 hours ago

Health

New drug to treat one of the deadliest cancers is 'the real deal,' oncologist says

Related coverage: New drug to treat one of the deadliest cancers is 'the real deal,' oncologist says ksl.com Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer Nature Pancreatic Cancer Specialists Getting a Jump on Daraxonrasib Medscape Patients in Illinois starting to receive experimental pancreatic cancer drug: ‘Game changer’ Chicago Tribune Stanford expands access to revolutionary pancreatic cancer drug Stanford Medicine

ksl.com · 3 hours ago

Health

MU School of Medicine receives $1 million cancer research grant

Related coverage: MU School of Medicine receives $1 million cancer research grant Columbia Missourian

Columbia Missourian · 5 hours ago

Health

FDA Approves PGDx Elio Tissue Complete CDx for Advanced Melanoma

Related coverage: FDA Approves PGDx Elio Tissue Complete CDx for Advanced Melanoma CancerNetwork

CancerNetwork · 6 hours ago